Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612891 | 0.86 | DPP4 (0.41) | SHBGKDM4EALDH1A1TDP1DPP4 | |
| SCHEMBL14145832 | 0.86 | DPP4 (0.41) | SHBGKDM4EALDH1A1TDP1DPP4 | |
| SCHEMBL12377378 | 0.86 | DPP4 (0.41) | SHBGKDM4EALDH1A1TDP1DPP4 | |
| SCHEMBL20247967 | 0.82 | SHBG (0.35) | SHBGALDH1A1DPP4GPR119HRH3 | |
| SCHEMBL23219669 | 0.81 | SPHK1 (0.41) | — | |
| SCHEMBL23467566 | 0.79 | SHBG (0.41) | SHBGKDM4EDPP4GPR119HRH3 | |
| SCHEMBL23114309 | 0.79 | SHBG (0.41) | SHBGKDM4EDPP4GPR119HRH3 | |
| SCHEMBL6628149 | 0.79 | SHBG (0.41) | SHBGKDM4EDPP4GPR119HRH3 | |
| SCHEMBL8285967 | 0.78 | PHGDH (0.37) | KDM4EALDH1A1TDP1HRH3TP53 | |
| SCHEMBL19388485 | 0.77 | SPHK1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | US | disclosed |
| US-7629339-B2 | inhibitors of protein kinases and are useful in treating cancer; 4-({5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-3-methoxy-butyric acid; anticarcinogenic agent | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | PHKG1, PHKG2, PRKCH | SHBG 4766/4885KDM4E 1481/4885ALDH1A1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.